IPHA
Innate Pharma
NASDAQ: IPHA · HEALTHCARE · BIOTECHNOLOGY
$1.48
+5.71% today
Updated 2026-04-29
Market cap
$138.87M
P/E ratio
—
P/S ratio
15.42x
EPS (TTM)
$-0.64
Dividend yield
—
52W range
$1 – $3
Volume
0.0M
Innate Pharma (IPHA) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-690.00%
ROE
-271.40%
ROA
-38.90%
Debt/equity
5.25x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $6.20M | $-6.04M | 64.47% | -116.85% | -97.53% |
| 2007 | $14.29M | $-8.92M | 80.64% | -63.62% | -62.41% |
| 2008 | $12.92M | $-9.85M | 80.21% | -85.16% | -76.23% |
| 2009 | $7.72M | $-14.63M | 56.62% | -201.33% | -189.55% |
| 2010 | $4.32M | $-13.66M | 20.67% | -316.90% | -316.16% |
| 2011 | $11.74M | $-6.98M | 86.05% | -64.48% | -59.45% |
| 2012 | $10.38M | $-3.20M | 33.86% | -32.63% | -30.83% |
| 2013 | $12.47M | $-2.89M | 39.22% | -22.40% | -23.19% |
| 2014 | $907000.00 | $-19.65M | -1,232.64% | -2,201.32% | -2,166.15% |
| 2015 | $17.91M | $-6.71M | -67.02% | -60.16% | -37.45% |
| 2016 | $56.16M | $12.64M | 13.41% | 13.48% | 22.51% |
| 2017 | $32.63M | $-48.38M | -105.33% | -122.53% | -148.28% |
| 2018 | $79.89M | $3.05M | 12.94% | 6.44% | 3.82% |
| 2019 | $68.97M | $-20.76M | 34.53% | -39.22% | -30.10% |
| 2020 | $69.77M | $-63.98M | 28.76% | 1.55% | -91.70% |
| 2021 | $12.11M | $-52.81M | -184.12% | -394.86% | -436.01% |
| 2022 | $57.67M | $-58.10M | 10.42% | -99.57% | -100.74% |
| 2023 | $51.90M | $-7.57M | 10.83% | -24.41% | -14.59% |
| 2024 | $12.62M | $-49.47M | 100.00% | -408.64% | -391.97% |
| 2025 | $2.79M | $-47.24M | 100.00% | -1,916.94% | -1,694.87% |